Skip to main content

Table 1 Mean score difference in PROs associated with a one-point difference in PASDAS or ScoreMDA

From: Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib

PRO*

Mean score difference (95% CI) in PROs associated with a one-point difference

PASDAS

ScoreMDA

EQ-5D-3L VAS, mm

 OPAL Broaden

−6.7 (− 7.2, − 6.3)

5.0 (4.6, 5.4)

 OPAL Beyond

− 6.9 (− 7.5, − 6.4)

5.5 (4.9, 6.1)

EQ-5D-3L UI

 OPAL Broaden

− 0.1 (− 0.1, − 0.1)

0.0 (0.0, 0.1)

 OPAL Beyond

−0.1 (− 0.1, − 0.1)

0.1 (0.1, 0.1)

FACIT-F total score

 OPAL Broaden

−2.8 (− 3.0, − 2.6)

1.9 (1.8, 2.1)

 OPAL Beyond

−3.3 (− 3.6, − 3.1)

2.7 (2.5, 3.0)

FACIT-F ED

 OPAL Broaden

−1.3 (− 1.4, − 1.2)

0.9 (0.8, 0.9)

 OPAL Beyond

−1.4 (− 1.6, − 1.3)

1.2 (1.1, 1.3)

FACIT-F ID

 OPAL Broaden

−1.6 (− 1.7, − 1.4)

1.1 (1.0, 1.2)

 OPAL Beyond

−1.9 (− 2.0, − 1.7)

1.5 (1.4, 1.7)

PGJS-VAS, mm

 OPAL Broaden

12.0 (11.6, 12.4)

−7.6 (− 8.0, − 7.2)

 OPAL Beyond

12.6 (12.1, 13.1)

− 9.2 (− 9.9, − 8.6)

PGJS-VAS-PsO, mm

 OPAL Broaden

9.9 (9.4, 10.5)

−6.0 (− 6.5, − 5.6)

 OPAL Beyond

10.4 (9.7, 11.1)

− 7.2 (− 8.0, − 6.5)

SF-36v2 PCS

 OPAL Broaden

NA

2.0 (1.9, 2.2)

 OPAL Beyond

NA

2.5 (2.3, 2.7)

SF-36v2 PF

 OPAL Broaden

NA

2.1 (2.0, 2.3)

 OPAL Beyond

NA

2.3 (2.1, 2.5)

Pain VAS, mm

 OPAL Broaden

9.9 (9.4, 10.4)

NA

 OPAL Beyond

10.7 (10.1, 11.2)

NA

HAQ-DI

 OPAL Broaden

0.2 (0.1, 0.2)

NA

 OPAL Beyond

0.2 (0.2, 0.2)

NA

  1. SF-36v2 PCS: norm-based scores were used (a score of 50 representing the mean for the general population, with higher scores indicating less impairment); ScoreMDA: continuous MDA with values from 0 to 7 (0–4, no MDA; 5–7, MDA)
  2. CI confidence interval, ED experience domain, EQ-5D-3L EuroQoL-Five Dimensions-Three Level Health Questionnaire, FACIT Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire-Disability Index, ID impact domain, MDA minimal disease activity, NA not assessed, Pain VAS Patient’s Assessment of Arthritis Pain visual analog scale, PASDAS Psoriatic Arthritis Disease Activity Score, PCS Physical Component Summary, PF physical functioning, PGJS-VAS Patient’s Global Joint and Skin Assessment visual analog scale, PGJS-VAS-PsO PGJS-VAS psoriasis question, PRO patient-reported outcome, SF-36v2 Short Form-36 Health Survey Version 2, acute, VAS visual analog scale
  3. *OPAL Broaden, N = 422; OPAL Beyond, N = 394; all treatment groups from each phase 3 study were pooled for analysis